Referencia número: HY-N4118

Cephaeline

(Synonyms: (-)-Cephaeline; NSC 32944 free base)

2 Cited Publications

Revisión del cliente

Based on 2 publication(s) in Google Scholar

Cephaeline ((-)-Cephaeline; NSC 32944) is a ferroptosis inducer, with broad-spectrum anticancer and antiviral activities. Cephaeline induces ferroptosis (Ferroptosis) by upregulating p53, inhibiting NRF2, activating ULK3, downregulating the expressions of SLC7A11 and GPX4 in a p53-dependent manner, reducing GSH and mitochondrial membrane potential, and increasing lipid peroxidation and iron accumulation. Cephaeline inhibits cancer cell proliferation, migration and tumor growth. Cephaeline inhibits Ebola virus (EBOV) VLP entry and infection, with IC₅₀ values of 3.27 μM and 22.18 μM respectively; it also inhibits Zika virus (ZIKV) NS5 RdRp activity (IC₅₀ = 976 nM), and binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RdRp and N protein, with K_d values of 8.9 μM and 53.8 μM respectively. Cephaeline can be used in studies related to breast cancer, lung cancer, COVID-19, EBOV and ZIKV infections.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.77%
No. CAS: 483-17-0
Fòrmula: C₂₈H₃₈N₂O₄
Peso molecular:466.61

Almacenamiento:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Cephaeline Chemical Structure

No. CAS: 483-17-0

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

EBOV

22.18 μM (IC₅₀)

ZIKV NS5 RdRp

976 nM (IC₅₀)

SARS-CoV-2 RdRp

8.9 μM (Kd)

SARS-CoV-2 N protein

53.8 μM (Kd)

GPX4

Ver todos los productos específicos de isoformas Glutathione Peroxidase :

GPX1
GPX4

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	3 μM Compound: 9	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31513408]
BT-549	IC₅₀	0.86 μg/mL Compound: 3	Cytotoxicity against human BT549 cells Cytotoxicity against human BT549 cells	[PMID: 12880315]
HEK-293T	CC₅₀	2 μM Compound: 97	Cytotoxicity against human HEK293T cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HEK293T cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 37597436]
HeLa	IC₅₀	>10 μg/mL Compound: 3	Inhibition of LFA1:CD11a/CD18/ICAM1-mediated human HL60 cell adhesion to human HeLa cells expressing ICAM1 by fluorescence analysis Inhibition of LFA1:CD11a/CD18/ICAM1-mediated human HL60 cell adhesion to human HeLa cells expressing ICAM1 by fluorescence analysis	[PMID: 12880315]
HeLa	IC₅₀	7.6 μM Compound: 9	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31513408]
HL-60	IC₅₀	14.9 μg/mL Compound: 3	Cytotoxicity against human HL60 cells by XTT assay Cytotoxicity against human HL60 cells by XTT assay	[PMID: 12880315]
Huh-7	CC₅₀	3.03 μM Compound: 97	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37597436]
KB	IC₅₀	0.33 μg/mL Compound: 3	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 12880315]
SK-MEL	IC₅₀	0.25 μg/mL Compound: 3	Cytotoxicity against human SK-MEL cells Cytotoxicity against human SK-MEL cells	[PMID: 12880315]
SK-OV-3	IC₅₀	0.1 μM Compound: 9	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31513408]
SK-OV-3	IC₅₀	0.18 μg/mL Compound: 3	Cytotoxicity against human SKOV3 cells Cytotoxicity against human SKOV3 cells	[PMID: 12880315]
Vero	CC₅₀	46.327 μM Compound: 97	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 37597436]
Vero	IC₅₀	5.3 μg/mL Compound: 3	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 12880315]

In Vitro

Cephaeline (2.5-320 nM; 72 h) potently inhibits the proliferation of 4T1 and MDA-MB-231 breast cancer cells, with IC₅₀ values of 38.89 nM and 50.29 nM, respectively^[2].
Cephaeline (80 nM; 24 h) inhibits the migration of 4T1 and MDA-MB-231 breast cancer cells^[2].
Cephaeline (14 day) inhibits colony formation of 4T1 and MDA-MB-231 breast cancer cells, and this effect is attenuated by p53 siRNA knockdown^[2].
Cephaeline (5-400 nM; 24-72 h) potently inhibits the viability of H460 and A549 human lung cancer cells in a time-dependent manner, with IC₅₀ values ranging from 35 nM to 89 nM^[1].
Cephaeline (0.01-30 μM; 48 h) inhibits the cell viability of mucoepidermoid carcinoma cell lines UM-HMC-1, UM-HMC-2 and UM-HMC-3A, with IC₅₀ values of 0.16 μM, 2.08 μM and 0.02 μM, respectively^[4].
Cephaeline (at the corresponding IC₅₀ concentration; 72 h) inhibits the cell growth of UM-HMC-1 and UM-HMC-2 mucoepidermoid carcinoma cell lines, while the growth inhibitory effect on UM-HMC-3A is not statistically significant^[4].
Cephaeline (at respective IC₅₀ concentrations) inhibits cell migration of the mucoepidermoid carcinoma cell lines UM-HMC-1, UM-HMC-2, and UM-HMC-3A, with the onset time of inhibition varying among different cell lines^[4].
Cephaeline (at the corresponding IC₅₀ concentration; 24-48 h) increases the acetylation level of histone H3 lysine 9 in the mucoepidermoid carcinoma cell lines UM-HMC-1, UM-HMC-2 and UM-HMC-3A^[4].
Cephaeline (at the corresponding IC₅₀ concentration; 24 h) reduces the level of ALDH+ cancer stem cells in UM-HMC-2 mucoepidermoid carcinoma cells, but increases the ALDH+ level in UM-HMC-1 and UM-HMC-3A cells^[4].
Cephaeline (at the corresponding IC₅₀ concentration; 5 days) completely inhibits tumor sphere formation in UM-HMC-1 and UM-HMC-2 mucoepidermoid carcinoma cells, and reduces tumor sphere formation in UM-HMC-3A cells^[4].
Cephaeline (20-80 nM; 72 h) reduces intracellular GSH levels in a concentration-dependent manner and increases intracellular MDA levels in 4T1 and MDA-MB-231 breast cancer cells^[2].
Cephaeline (20-80 nM; 72 h) increases intracellular ROS levels in 4T1 and MDA-MB-231 breast cancer cells in a concentration-dependent manner^[2].
Cephaeline (20-80 nM; 72 h) increases the levels of total iron and Fe²⁺ in 4T1 and MDA-MB-231 breast cancer cells in a concentration-dependent manner^[2].
Cephaeline (20-80 nM; 72 h) downregulates the protein expression of SLC7A11 and GPX4 in a concentration-dependent manner, and upregulates the protein expression of p53 in 4T1 and MDA-MB-231 breast cancer cells^[2].
The ferroptosis and cell death induced in human lung cancer cells H460 and A549 by cephaeline (100 nM; 24 h) are mediated by targeting NRF2, as pretreatment with the NRF2 agonist TBHQ reverses these effects^[1].
Cephaeline (80 nM; 72 h) induces ferroptosis-related changes (decreased GSH levels, increased MDA and ROS levels, downregulated expression of SLC7A11 and GPX4) in 4T1 and MDA-MB-231 breast cancer cells, and these effects are blocked by p53 siRNA knockdown^[2].
Cephaeline (25-100 nM; 24 h) increases intracellular iron levels and reactive oxygen species levels in H460 and A549 human lung cancer cells^[1].
Cephaeline (25-100 nM; 24 h) regulates the expression of ferroptosis- and iron metabolism-related genes in H460 and A549 human lung cancer cells, downregulates the expression of GPX4, SLC7A11 and SLC40A1, and upregulates the expression of transferrin^[1].
Cephaeline 25-100 nM; 24 h) downregulates the protein levels of GPX4, SLC7A11, SLC40A1 and NRF2, while upregulates the protein expression of transferrin in human lung cancer H460 and A549 cells^[1].
Cephaeline (25-100 nM; 24 h) induces lipid peroxidation in human lung cancer cells H460 and A549, which can be detected by increased levels of malondialdehyde^[1].
Cephaeline (25-100 nM; 24 h) reduces glutathione levels in H460 and A549 human lung cancer cells, thereby impairing their antioxidant capacity^[1].
Cephaeline (1.950-50 μM; 90 s injection, 180 s dissociation) binds to purified SARS-CoV-2 nsp12 with a K_D value of 19.6 μM^[3].
Cephaeline (1.301-50 μM; 90 s injection, 180 s dissociation) binds to the SARS-CoV-2 nsp12-nsp7-nsp8-RNA complex with a K_D value of 8.94 μM^[3].
Cephaeline (1.301-50 μM; 90 s injection, 180 s dissociation) binds to purified SARS-CoV-2 N protein with a K_D value of 58.24 μM^[3].
Cephaeline (24 h) potently inhibits the replication of SARS-CoV-2 in Vero E6 cells, with an EC₅₀ of 0.0123 μM^[3].
Cephaeline (1 h) inhibits ZIKV NS5 RdRp polymerase activity in HEK293 cells, with an IC₅₀ value of 976 nM^[5].

Cephaeline (72 h) inhibits Ebola virus VLP entry into HeLa cells with an IC₅₀ value of 3.27 μM, and suppresses Ebola virus infection in Vero E6 cells with an IC₅₀ value of 22.18 nM^[5].
Cephaeline (24 h) exhibits cytotoxicity in Vero E6, Huh-7 and HEK293T cells, with CC₅₀ values of 49.048, 3.035 and 1.995 μM, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[1]

Cell Line:

H460 and A549 human lung cancer cell lines
Concentration:

25, 50, 100 nM
Incubation Time:

24 h
Result:

Significantly downregulated the expression of antioxidant-related genes GPX4 and SLC7A11 in both H460 and A549 cells.
Upregulated the iron influx-promoting gene transferrin in both H460 and A549 cells.
Downregulated the iron efflux-regulating gene SLC40A1 in both H460 and A549 cells.

Cell Viability Assay^[1]

Cell Line:

H460 and A549 human lung cancer cell lines
Concentration:

5, 15, 25, 50, 100, 200, 400 nM
Incubation Time:

24 h; 48 h; 72 h
Result:

Exhibited concentration- and time-dependent inhibitory effects on H460 and A549 cell viability.
Reduced H460 cell viability with IC₅₀ values of 88 nM at 24 h, 58 nM at 48 h, and 35 nM at 72 h.
Reduced A549 cell viability with IC₅₀ values of 89 nM at 24 h, 65 nM at 48 h, and 43 nM at 72 h.

Western Blot Analysis^[1]

Cell Line:

H460 and A549 human lung cancer cell lines
Concentration:

25, 50, 100 nM
Incubation Time:

24 h
Result:

Significantly reduced protein levels of GPX4, SLC7A11, SLC40A1, and the antioxidant regulatory protein NRF2 in both H460 and A549 cells.
Increased transferrin protein levels in both H460 and A549 cells.
Produced results consistent with RT-qPCR gene expression findings.

Cell Viability Assay^[1]

Cell Line:

H460 and A549 human lung cancer cell lines
Concentration:

100 nM
Incubation Time:

24 h
Result:

Induced cell death in both H460 and A549 cells.
Induced increases in lipid ROS and lipid peroxidation in both H460 and A549 cells.
Reduced intracellular GSH levels in both H460 and A549 cells.
Induced LDH release in both H460 and A549 cells.
Downregulated GPX4 and SLC7A11 proteins in both H460 and A549 cells.
Had all above effects significantly reversed by pre-treatment with NRF2 agonist TBHQ.

Cell Viability Assay^[2]

Cell Line:

murine 4T1 breast cancer cells, human MDA-MB-231 breast cancer cells
Concentration:

2.5, 5, 10, 20, 40, 80, 160 and 320 nM
Incubation Time:

72 h
Result:

Inhibited cell viability and proliferation in a dose-dependent manner in both cell lines.
Exhibited an IC50 value of 38.89 nM for 4T1 cells.
Exhibited an IC50 value of 50.29 nM for MDA-MB-231 cells.

Cell Migration Assay ^[2]

Cell Line:

murine 4T1 breast cancer cells, human MDA-MB-231 breast cancer cells
Concentration:

80 nM
Incubation Time:

24 h
Result:

Significantly reduced the migratory capacity of both 4T1 and MDA-MB-231 cells, as measured by decreased wound closure relative to untreated controls.

ELISA Assay^[2]

Cell Line:

murine 4T1 breast cancer cells, human MDA-MB-231 breast cancer cells
Concentration:

20, 40 and 80 nM
Incubation Time:

72 h
Result:

Caused a concentration-dependent decrease in intracellular GSH levels in both 4T1 and MDA-MB-231 cells.
Caused a corresponding concentration-dependent increase in intracellular MDA levels in both 4T1 and MDA-MB-231 cells.

Immunofluorescence^[2]

Cell Line:

murine 4T1 breast cancer cells, human MDA-MB-231 breast cancer cells
Concentration:

20, 40 and 80 nM
Incubation Time:

72 h
Result:

Increased ROS levels in 4T1 and MDA-MB-231 breast cancer cells in a concentration-dependent manner.

Western Blot Analysis^[2]

Cell Line:

murine 4T1 breast cancer cells, human MDA-MB-231 breast cancer cells
Concentration:

20, 40 and 80 nM
Incubation Time:

72 h
Result:

Caused a concentration-dependent downregulation of SLC7A11 protein expression in both 4T1 and MDA-MB-231 cells.
Caused a concentration-dependent downregulation of GPX4 protein expression in both 4T1 and MDA-MB-231 cells.
Caused a concentration-dependent upregulation of p53 protein expression in both 4T1 and MDA-MB-231 cells.
Increased nuclear p53 fluorescence intensity in both cell lines via immunofluorescence staining.

Cell Proliferation Assay^[4]

Cell Line:

human mucoepidermoid carcinoma cell lines UM-HMC-1, UM-HMC-2, UM-HMC-3A
Concentration:

0.16 μM (UM-HMC-1); 2.08 μM (UM-HMC-2); 0.02 μM (UM-HMC-3A)
Incubation Time:

24 h, 48 h, 72 h
Result:

Inhibited cell growth in UM-HMC-1 and UM-HMC-2, with the largest difference between treated and control groups observed at 72h.
Inhibited growth in UM-HMC-3A but did not reach statistical significance.

Cell Migration Assay ^[4]

Cell Line:

human mucoepidermoid carcinoma cell lines UM-HMC-1, UM-HMC-2, UM-HMC-3A
Concentration:

0.16 μM (UM-HMC-1); 2.08 μM (UM-HMC-2); 0.02 μM (UM-HMC-3A)
Incubation Time:

6 h, 12 h, 24 h, 48 h
Result:

Reduced cell migration in all three cell lines.
Induced significant inhibition in UM-HMC-1 at 48h and 60h.
Induced reduced migration in UM-HMC-2 and UM-HMC-3A as early as 24h after treatment.

Immunofluorescence^[4]

Cell Line:

human mucoepidermoid carcinoma cell lines UM-HMC-1, UM-HMC-2, UM-HMC-3A
Concentration:

0.16 μM (UM-HMC-1); 2.08 μM (UM-HMC-2); 0.02 μM (UM-HMC-3A)
Incubation Time:

24 h, 48 h
Result:

Induced significant H3K9ac acetylation in all three cell lines as early as 24h after treatment, and acetylation levels remained elevated through 48h.

In Vivo

Cephaeline (5-10 mg/kg; i.p.; once daily; 12 days) exhibits dose-dependent anti-lung cancer efficacy in BALB/c-nu mice bearing subcutaneous H460 xenografts, and induces ferroptosis-related protein changes in tumor tissues^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c-nu (5-week-old female) were injected subcutaneously in the right back with 1 × 10⁶ H460 lung cancer cells (dissolved in 0.1 mL PBS) to establish a subcutaneous tumor model^[1]
Dosage:

5 mg/kg; 10 mg/kg
Administration:

i.p.; daily; 12 days
Result:

Exerted significant in vivo antitumour effects at 5 mg/kg and 10 mg/kg doses.
Achieved an ED₅₀ of 3 mg/kg and minimum effective concentration of 2.5 mg/kg in the subcutaneous tumor xenograft model.
Demonstrated equivalent anti-lung cancer efficacy to erastin at 10 mg/kg dose.
Caused no significant differences in body weight compared with control mice.
Induced changes in ferroptosis-related protein expression in tumor tissue consistent with in vitro findings.

Chemical Information

No. CAS 483-17-0
Appearance Solid
Peso molecular 466.61
Fòrmula C₂₈H₃₈N₂O₄
Color Off-white to light yellow
SMILES

OC1=CC2=C([C@@H](C[C@@H]3[C@@H](CC)CN4CCC5=CC(OC)=C(OC)C=C5[C@]4([H])C3)NCC2)C=C1OC
Synonyms

(-)-Cephaeline; NSC 32944 free base
Structure Classification
- Alkaloids
- Isoquinoline Alkaloids
- Phenols
- Monophenols
Initial Source
- Plants
- other families
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All Cell Proliferation/Viability AssayCell Migration/Invasion AssayWB

Sort by:

Journal Impact Factor

J Cancer Res Clin Oncol

Prognostic value of amino acid metabolism-related gene expression in invasive breast carcinoma. [Abstract]

2023 Oct;149(13):11117-11133. PMID: 37340191

Cephaeline purchased from MedChemExpress. Usage Cited in: J Cancer Res Clin Oncol. 2023 Oct;149(13):11117-11133. [Abstract]

MDA-MB-231 and MCF-7 cells were treated with different dose of Cephaeline (0.1, 0.5, 1, 5, 10 μM) and cell viability were calculated by Cell Counting Kit-8.

Cephaeline purchased from MedChemExpress. Usage Cited in: J Cancer Res Clin Oncol. 2023 Oct;149(13):11117-11133. [Abstract]

Representative images of cell scratch-wound healing test taken by a microscope at × 100 magnification treated with Cephaeline (0.2, 0.4 μM).

Cephaeline purchased from MedChemExpress. Usage Cited in: J Cancer Res Clin Oncol. 2023 Oct;149(13):11117-11133. [Abstract]

Representative western blots for PI3K/AKT signal pathway and HIF-1α under different doses of Cephaeline (0.1, 0.2, 0.3, 0.4, 0.5 μM).
Daru

Cephaeline promotes ferroptosis in breast cancer via p53/SLC7A11/GPX4 axis. [Abstract]

2026 Jun 19;34(2):38. PMID: 42319734

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (214.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 33.33 mg/mL (71.43 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1431 mL

10.7156 mL

21.4312 mL

5 mM

0.4286 mL

2.1431 mL

4.2862 mL

10 mM

0.2143 mL

1.0716 mL

2.1431 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (296 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Chen P, et al. Cephaeline promotes ferroptosis by targeting NRF2 to exert anti-lung cancer efficacy. Pharmaceutical biology. 2024 Dec;62(1):195-206. [Content Brief]

[2]. Li X, et al. Cephaeline promotes ferroptosis in breast cancer via p53/SLC7A11/GPX4 axis. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2026 Jun 19;34(2):38. [Content Brief]

[3]. Ren PX, et al. A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors. Acta pharmacologica Sinica. 2022 Feb;43(2):483-493. [Content Brief]

[4]. Silva LC, et al. Cephaeline is an inductor of histone H3 acetylation and inhibitor of mucoepidermoid carcinoma cancer stem cells. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2022 Jul;51(6):553-562. [Content Brief]

[5]. Yang S, et al. Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discov. 2018 Jun 5;4:31.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	2.1431 mL	10.7156 mL	21.4312 mL	53.5779 mL
	5 mM	0.4286 mL	2.1431 mL	4.2862 mL	10.7156 mL
	10 mM	0.2143 mL	1.0716 mL	2.1431 mL	5.3578 mL
	15 mM	0.1429 mL	0.7144 mL	1.4287 mL	3.5719 mL
	20 mM	0.1072 mL	0.5358 mL	1.0716 mL	2.6789 mL
	25 mM	0.0857 mL	0.4286 mL	0.8572 mL	2.1431 mL
	30 mM	0.0714 mL	0.3572 mL	0.7144 mL	1.7859 mL
	40 mM	0.0536 mL	0.2679 mL	0.5358 mL	1.3394 mL
	50 mM	0.0429 mL	0.2143 mL	0.4286 mL	1.0716 mL
	60 mM	0.0357 mL	0.1786 mL	0.3572 mL	0.8930 mL
DMSO	80 mM	0.0268 mL	0.1339 mL	0.2679 mL	0.6697 mL
DMSO	100 mM	0.0214 mL	0.1072 mL	0.2143 mL	0.5358 mL

Bioz

Cephaeline

2 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Cephaeline

Anisomycin

N-Ethylmaleimide

Dimethyl sulfoxide, meets analytical specification of Ch.P.

PEG300

PEG400

Tween 80

Tubercidin

Cephaeline (Standard)

Navitoclax

FGI-106 tetrahydrochloride

Desaminotyrosine

7-Hydroxyflavone

Publications Citing Use of MedChemExpress (MCE) Cephaeline

Ver todos los productos específicos de isoformas Glutathione Peroxidase

Actividad biológica

Chemical Information

Publications (2)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Cephaeline

Anisomycin

N-Ethylmaleimide

Dimethyl sulfoxide, meets analytical specification of Ch.P.

PEG300

PEG400

Tween 80

Tubercidin

Cephaeline (Standard)

Navitoclax

FGI-106 tetrahydrochloride

Desaminotyrosine

7-Hydroxyflavone

Publications Citing Use of MedChemExpress (MCE) Cephaeline

Ver todos los productos específicos de isoformas Glutathione Peroxidase

Actividad biológica

Chemical Information

Publications (2)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Cephaeline Related Classifications

HY-N4118 Related Classifications

Bioz